ALLMedicine™ Androgenetic Alopecia Center

Jan 14th, 2022 - A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.

Jan 11th, 2022 - Practice Essentials Androgenetic (or pattern) alopecia is a genetically determined disorder characterized by the gradual conversion of terminal hairs into indeterminate, and finally into vellus, hairs. It is an extremely common disease that affect...

Jan 11th, 2022 - Medication Summary Only 2 medications have been shown to be effective in the treatment of androgenetic alopecia: minoxidil and finasteride. Minoxidil is applied topically and available as 2% or 5% solutions. Finasteride is taken orally. Next: Vaso...

Jan 11th, 2022 - History The onset of androgenetic alopecia is gradual. Men present with gradual thinning in the temporal areas, producing a reshaping of the anterior part of the hairline. For the most part, the evolution of baldness progresses according to the No...

Jan 11th, 2022 - Medical Care Only two drugs currently have US Food and Drug Administration (FDA)–approved indications for treatment of androgenetic alopecia: minoxidil and finasteride. Minoxidil Although the method of action is essentially unknown, minoxidil appe...

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

Jan 14th, 2022 - A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.

Jan 4th, 2022 - The purpose of this pilot study is to determine if the Revian Red All LED cap shows potential to be an effective treatment for CCCA by recruiting hair follicles back to anagen growth or by improving inflammation. The primary outcome is to determin...

Dec 7th, 2021 - This is a single institution, open-label, baseline-controlled, prospective study evaluating the use of a non-ablative fractionated thulium laser and topical autologous platelet-rich plasma (PRP) vs. PRP injection for the treatment of male androgen...

Nov 22nd, 2021 - Platelet-rich plasma (PRP) has been used for more than a decade in the treatment of androgenetic alopecia and hair loss. Platelets contain a range of growth factors , namely vascular endothelial growth factor (VEGF), insulin-like growth factor (IG...

Oct 26th, 2021 - INTRODUCTION: An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019. Belonging to the family Beta-coronavirus, this...

Nov 4th, 2021 - Hair follicle miniaturization was a prominent feature of persistent chemotherapy-induced alopecia (pCIA) in breast cancer survivors who presented to four specialty hair clinics, and treatment with minoxidil (sometimes with antiandrogen therapy) wa...

Aug 30th, 2021 - While some prefer the bald look, those who are unhappy about losing their hair might be interested to hear about a new approach where scientists use mechanical stimulation to promote hair regrowth. Male- or female-pattern baldness, also known as a...

Aug 10th, 2021 - Androgenetic alopecia significantly impairs patients' overall quality of life and emotional health, but does not have a notable impact on the incidence of depression, according a systematic review and meta-analysis of 41 studies. "Hair loss affect...

Aug 3rd, 2021 - NEW YORK (Reuters Health) - Acute telogen effluvium (TE) following COVID-19 appears to occur sooner, with quicker resolution, than when TE is triggered by other events, clinicians have observed. TE is form of alopecia characterized by diffuse hair...

Mar 24th, 2021 - Anagen effluvium during chemotherapy is common, typically beginning within 1 month of treatment onset and resolving by 6 months after the final course. 1 Permanent chemotherapy-induced alopecia (PCIA), in which hair loss persists beyond 6 months af.